tocotrienol : A tocol in which the hydrocarbon chain at position 2 contains three double bonds. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 9929901 |
| CHEMBL ID | 120643 |
| CHEBI ID | 197268 |
| SCHEMBL ID | 1448780 |
| SCHEMBL ID | 1081622 |
| MeSH ID | M0370452 |
| Synonym |
|---|
| tocotrienol |
| ccris 7711 |
| tocotrienols , |
| CHEMBL120643 |
| (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol |
| CHEBI:197268 |
| 2-methyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trienyl]-3,4-dihydrochromen-6-ol |
| NCGC00186586-01 |
| SCHEMBL1448780 |
| unii-0867i0n41v |
| 0867i0n41v , |
| 6829-55-6 |
| SCHEMBL1081622 |
| 2h-1-benzopyran-6-ol, 3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)- |
| 2-methyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]-3,4-dihydro-2h-1-benzopyran-6-ol |
| DB12647 |
| GJJVAFUKOBZPCB-ZGRPYONQSA-N |
| Q27236375 |
| 97530-73-9 |
| 3,4-dihydro-2-methyl-2-[(3e,7e)-4,8,12-trimethyl-3,7,11-tridecatrien-1-yl]-2h-1-benzopyran-6-ol |
| DTXSID601336446 |
| 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trien-1-yl)chroman-6-ol |
| 2-methyl-2-((3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl)chroman-6-ol |
Tocotrienols are a class of vitamin E reported to be potent antioxidants, besides having the ability to inhibit the HMG-CoA reductase enzyme. They have shown to be a potent antioxidant, anti-inflammatory, and antifibrotic agent.
Tocotrienols have been shown to inhibit the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity. They have been reported to exert anticancer, anti-inflammatory, antioxidant, cardio-protective and boneprotective effects through modulation of NFκB signalling pathway.
Tocotrienols can suppress the growth of different malignancies, including those of breast, lung, ovary, prostate, liver, brain, colon, myeloma, and pancreas. Tocotrianols also inhibit vascularization-reducing proliferation, migration and tube formation.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Tocotrienols can suppress the growth of different malignancies, including those of breast, lung, ovary, prostate, liver, brain, colon, myeloma, and pancreas." | ( Molecular Mechanisms of Action of Tocotrienols in Cancer: Recent Trends and Advancements. Aggarwal, V; Chaudhary, A; Garg, VK; Jain, A; Kashyap, D; Sak, K; Sethi, G; Tuli, HS; Yerer, MB, 2019) | 1.51 |
| "Tocotrienols also inhibit vascularization-reducing proliferation, migration and tube formation." | ( Chemoprevention of tocotrienols: the mechanism of antiproliferative effects. Wada, S, 2009) | 1.4 |
Tocotrienols treatment induced increases in α-tocopherol levels of 4-fold and 6-fold in plasma and platelets, respectively. Treatment with tocotrienols may protect neurite function through its neuroprotective function.
The Cosmetic Ingredient Review (CIR) Expert Panel (Panel) assessed the safety of 14 tocopherols and tocotrienols. The panel concluded these ingredients are safe as used in cosmetics.
| Excerpt | Reference | Relevance |
|---|---|---|
| "To evaluate and compare the pharmacokinetic parameters, especially bioavailability, of annatto-based tocotrienol with palm tocotrienol-rich fraction in healthy human volunteers for better therapeutic outcome." | ( Pharmacokinetics and bioavailability of tocotrienols in healthy human volunteers: a systematic review. Farhat, K; Khan, DA; Khan, MA; Noor, M; Rafique, S; Sharif, M, 2023) | 1.18 |
| " Pharmacokinetic parameters of annatto-based tocotrienol were better than palm-derived tocotrienol." | ( Pharmacokinetics and bioavailability of tocotrienols in healthy human volunteers: a systematic review. Farhat, K; Khan, DA; Khan, MA; Noor, M; Rafique, S; Sharif, M, 2023) | 1.18 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The present study was performed to investigate the effect of astaxanthin in combination with other antioxidants against oxidative damage in streptozotocin (STZ)-induced diabetic Osteogenic Disorder Shionogi (ODS) rats." | ( Effect of astaxanthin in combination with alpha-tocopherol or ascorbic acid against oxidative damage in diabetic ODS rats. Nakano, M; Nguyen, VC; Onodera, A; Saito, E; Takahashi, J; Tanabe, M; Yajima, K, 2008) | 0.35 |
| "We conducted a double-blinded, placebo-controlled pilot trial to test the effectiveness of adjuvant tocotrienol therapy in combination with tamoxifen for five years in women with early breast cancer." | ( Effectiveness of tocotrienol-rich fraction combined with tamoxifen in the management of women with early breast cancer: a pilot clinical trial. Abdul Razak, G; Gomez, PA; Nesaretnam, K; Selvaduray, KR; Veerasenan, SD, 2010) | 0.36 |
Tocotrienols, however, have poor oral bioavailability and were therefore entrapped into parenteral nanoemulsions. The effect of nanoencapsulation on the oral bio availability and tissue distribution of tocotrienols were investigated.
| Excerpt | Reference | Relevance |
|---|---|---|
| " Although the antioxidant activity of tocotrienols is higher than that of tocopherols, tocotrienols have a lower bioavailability after oral ingestion." | ( Molecular aspects of alpha-tocotrienol antioxidant action and cell signalling. Packer, L; Rimbach, G; Weber, SU, 2001) | 0.58 |
| "We have investigated the pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under fed and fasted conditions in eight healthy volunteers." | ( Pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under different food status. Wong, JW; Yap, SP; Yuen, KH, 2001) | 0.77 |
| " It is important to characterize the active components in garlic and their bioavailability after ingestion." | ( Effects on the human serum lipoprotein profile of beta-glucan, soy protein and isoflavones, plant sterols and stanols, garlic and tocotrienols. Brouns, F; Hornstra, G; Kerckhoffs, DA; Mensink, RP, 2002) | 0.52 |
| "A study was conducted to evaluate the bioavailability of alpha-, gamma- and delta-tocotrienols administered via oral, intravenous, intramuscular and intraperitoneal routes in rats." | ( Influence of route of administration on the absorption and disposition of alpha-, gamma- and delta-tocotrienols in rats. Lim, AB; Yap, SP; Yuen, KH, 2003) | 0.76 |
| "A single dose comparative bioavailability study was conducted to evaluate the bioavailability of tocotrienols from two self-emulsifying formulations, one of which produced an emulsion that readily lipolysed under in vitro condition (SES-A), while the other produced a finer dispersion with negligible lipolysis (SES-B) in comparison with that of a non-self-emulsifying formulation in soya oil." | ( Influence of lipolysis and droplet size on tocotrienol absorption from self-emulsifying formulations. Yap, SP; Yuen, KH, 2004) | 0.54 |
| " The report that the affinity of TTP to bind (alpha-TCT is an order of magnitude lower than that for alpha-TCP questions the bioavailability of orally taken TCT to tissues." | ( Natural vitamin E alpha-tocotrienol: retention in vital organs in response to long-term oral supplementation and withdrawal. Ezziddin, O; Khanna, S; Patel, V; Roy, S; Sen, CK, 2006) | 0.33 |
| "The study showed a good bioavailability of these vitamins and increment due to supplementation." | ( Plasma vitamin C and tocotrienols changes in response to dietary supplementation among young male adults. Das, S; Fatimah, IS; Khairul, O; Lee, CC; Mohamad, J; Poh, BK; Zahara, AM, 2010) | 0.68 |
| "To determine the bioavailability of tocotrienol complex with gamma-cyclodextrin, the effects of tocotrienol/gamma-cyclodextrin complex on tocotrienol concentration in rat plasma and tissues were studied." | ( Complexation of tocotrienol with gamma-cyclodextrin enhances intestinal absorption of tocotrienol in rats. Ichikawa, T; Ikeda, S; Nakata, D; Terao, K; Uchida, T; Uekaji, Y; Watanabe, T; Yano, T, 2010) | 0.36 |
| " To circumvent these limitations in oral absorption of tocotrienols, investigators have developed novel prodrug derivatives and nanoparticle delivery systems that greatly enhance tocotrienol bioavailability and therapeutic responsiveness." | ( The value of tocotrienols in the prevention and treatment of cancer. El Sayed, KA; Kaddoumi, A; Nazzal, S; Sylvester, PW, 2010) | 0.98 |
| " The low bioavailability and rapid excretion of T(3) represents a major hurdle in their preventive use." | ( Do tocotrienols have potential as neuroprotective dietary factors? Chin, XW; Eckert, GP; Frank, J; Rimbach, G; Schrader, C, 2012) | 1 |
| " However recent studies tried to increase the bioavailability with esterification and combination use." | ( Cellular protection and therapeutic potential of tocotrienols. Batirel, S; Catalgol, B; Ozer, NK, 2011) | 0.62 |
| " Low-phytate (LP) grain is distinguished by containing not only a reduced level of phytate P but also an increased level of inorganic P, resulting in greater bioavailability of P and mineral cations in animal diets." | ( Compositional equivalence of barleys differing only in low- and normal-phytate levels. Bregitzer, P; Hicks, KB; Liu, K; Moreau, RA, 2012) | 0.38 |
| " However, its potential in cancer therapy is limited by its poor bioavailability and its inability to specifically reach tumors at therapeutic concentrations after intravenous administration." | ( Delivery of the vitamin E compound tocotrienol to cancer cells. Dufès, C, 2011) | 0.37 |
| " The purpose of the current study was to evaluate the in vivo oral bioavailability of vitamin E isoforms, δ-tocotrienol (δ-T3) and γ-tocotrienol (γ-T3) administered as SEDDS, as compared to commercially available UNIQUE E® Tocotrienols capsules." | ( Nonlinear absorption kinetics of self-emulsifying drug delivery systems (SEDDS) containing tocotrienols as lipophilic molecules: in vivo and in vitro studies. Alayoubi, A; Alqahtani, S; Kaddoumi, A; Nazzal, S; Sylvester, PW, 2013) | 0.8 |
| " The reason behind this discrepancy might be due to the safety and bioavailability of the currently used oral statins." | ( A review on the use of statins and tocotrienols, individually or in combination for the treatment of osteoporosis. Abdul-Majeed, S; Mohamed, N; Soelaiman, IN, 2013) | 0.67 |
| " Its clinical use, however, is limited by poor oral bioavailability and short half-life." | ( Effect of PEG surface conformation on anticancer activity and blood circulation of nanoemulsions loaded with tocotrienol-rich fraction of palm oil. Alayoubi, A; Alqahtani, S; Kaddoumi, A; Nazzal, S, 2013) | 0.39 |
| " Tocotrienols, however, have poor oral bioavailability and were therefore entrapped into parenteral nanoemulsions for parenteral administration." | ( Entrapment into nanoemulsions potentiates the anticancer activity of tocotrienols against the highly malignant (+SA) mouse mammary epithelial cells. Alayoubi, A; Ayoub, NM; Malaviya, A; Nazzal, S; Sylvester, PW, 2014) | 1.55 |
| " This single-dose, randomized, crossover study aimed to compare the safety and bioavailability of a new formulation of Gamma Delta Tocotrienol (GDT) in comparison with the existing Tocotrienol-rich Fraction (TRF) in terms of gamma and delta isomers in healthy volunteers." | ( A new formulation of Gamma Delta Tocotrienol has superior bioavailability compared to existing Tocotrienol-Rich Fraction in healthy human subjects. Bhoo-Pathy, N; Chik, Z; Choudhury, RB; Fuang, HG; Jabir, RS; Meganathan, P; Nesaretnam, K; Taib, NA, 2015) | 0.42 |
| " Tocotrienol-containing plant foods and tocotrienol derivatives and formulations with enhanced bioavailability may offer a novel approach in AD prevention and treatment." | ( Potential of tocotrienols in the prevention and therapy of Alzheimer's disease. Mo, H; Xia, W, 2016) | 0.8 |
| " Owing to a difference in the affinity of T3 and Toc for the α-tocopherol transfer protein, the bioavailability of orally ingested T3 is lower than that of Toc." | ( Synergistic Anticancer Effect of Tocotrienol Combined with Chemotherapeutic Agents or Dietary Components: A Review. Eitsuka, T; Miyazawa, T; Nakagawa, K; Nishida, H; Tatewaki, N, 2016) | 0.43 |
| "CC-60 and TRF-80 supplementation increased bioavailability of palm-based carotenes and tocotrienols but had no effects, superior or detrimental, on vascular function or CVD risk factors." | ( Short term effects of palm-tocotrienol and palm-carotenes on vascular function and cardiovascular disease risk: A randomised controlled trial. Abeywardena, MY; Brinkworth, GD; Stonehouse, W; Thompson, CH, 2016) | 0.66 |
| " Compared to tocopherols, less research has been conducted on these compounds because of their low bioavailability and distribution in plant tissues." | ( Advances in Genetic Improvement for Tocotrienol Production: A Review. Abdullah, SNA; Babura, SR; Khaza Ai, H, 2017) | 0.46 |
| " Thus, SIRT1 may regulate vitamin E transportation and bioavailability at cellular level." | ( Cellular Uptake and Bioavailability of Tocotrienol-Rich Fraction in SIRT1-Inhibited Human Diploid Fibroblasts. Abdullah, A; Jaafar, F; Makpol, S, 2018) | 0.48 |
| " The increased bioavailability of VE by antibiotics is probably due to increased absorption of VE or its decreased degradation by gut microbes." | ( Effects of antibiotics on degradation and bioavailability of different vitamin E forms in mice. Lee, MJ; Lin, Y; Liu, AB; Ran, L; Xie, P; Yang, CS, 2019) | 0.51 |
| " However, the bioavailability of these metabolites has not been well characterized." | ( Tocopherols and Tocotrienols Are Bioavailable in Rats and Primarily Excreted in Feces as the Intact Forms and 13'-Carboxychromanol Metabolites. Jiang, Q; Liu, KY, 2020) | 0.9 |
| " The cellular levels of vitamin E were quantified to determine bioavailability at cellular levels." | ( Analysis of expression of vitamin E-binding proteins in H2O2 induced SK-N-SH neuronal cells supplemented with α-tocopherol and tocotrienol-rich fraction. Abd Hamid, R; Chang, SK; Chiroma, AA; Khaza'ai, H; Zainal, Z; Zakaria, ZA, 2020) | 0.56 |
| "Tocotrienol has been shown to prevent bone loss in animal models of postmenopausal osteoporosis, but the low oral bioavailability might limit its use." | ( Therapeutic potential of annatto tocotrienol with self-emulsifying drug delivery system in a rat model of postmenopausal bone loss. Chin, KY; Ima-Nirwana, S; Mohamad, NV, 2021) | 0.62 |
| " Recent studies have focused on targeted drug delivery by enhancing the bioavailability through carriers, self-sustained emulsions, nanoparticles, and ethosomes." | ( Revisiting the therapeutic potential of tocotrienol. Mathai, M; Ranasinghe, R; Zulli, A, 2022) | 0.72 |
| " Delta isomer of annatto-based tocotrienol had the highest bioavailability amongst all isomers of tocotrienol." | ( Pharmacokinetics and bioavailability of tocotrienols in healthy human volunteers: a systematic review. Farhat, K; Khan, DA; Khan, MA; Noor, M; Rafique, S; Sharif, M, 2023) | 1.18 |
Tocotrienols have very short plasma half-lives. They require dosing at very high levels to achieve necessary therapeutic benefits. The antiproliferative and cytotoxic effects of tocotrienols are mediated through different mechanisms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The in vitro cholesterol-biosynthesis-inhibitory and HMGR-suppressive activities in HepG2 cells of an expanded series of benzopyran and tetrahydronaphthalene isosteres and the hypocholesterolemic activity of selected compounds assessed in orally dosed chickens are presented." | ( Inhibitors of cholesterol biosynthesis. 2. Hypocholesterolemic and antioxidant activities of benzopyran and tetrahydronaphthalene analogues of the tocotrienols. Deason, ME; Dischino, DD; Gillespie, E; Parker, RA; Pearce, BC; Qureshi, AA; Volk, K; Wright, JJ, 1994) | 0.49 |
| " The tocotrienol-rich fraction (TRF) of palm oil inhibited growth of MCF7 cells in both the presence and absence of estradiol with a nonlinear dose-response but such that complete suppression of growth was achieved at 8 microg/mL." | ( Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status. Darbre, P; Dils, R; Nesaretnam, K; Stephen, R, 1998) | 1.74 |
| " In Experiment 2, we examined whether sesaminol caused enhanced absorption of alpha-tocopherol and alpha-tocotrienol in a dosage regimen supplying T-mix and sesaminol on alternating days and observed significantly higher levels of alpha-tocopherol and alpha-tocotrienol in rats fed sesaminol, even without simultaneous intake, compared to those in rats without sesaminol." | ( Effect of sesaminol on plasma and tissue alpha-tocopherol and alpha-tocotrienol concentrations in rats fed a vitamin E concentrate rich in tocotrienols. Iizuka, Y; Ikeda, I; Ikeda, S; Yamashita, K, 2002) | 0.52 |
| " Furthermore, dose-response studies show that growth inhibitory doses of tocotrienols are 5-6 times lower than their corresponding lethal doses, suggesting that the antiproliferative and cytotoxic effects of tocotrienols are mediated through different mechanisms." | ( Mechanisms mediating the antiproliferative and apoptotic effects of vitamin E in mammary cancer cells. Shah, SJ; Sylvester, PW, 2005) | 0.56 |
| " Adult Beagle dogs (n 8) were administered a single oral dosage of a TCT-rich fraction (TRF; 40 mg/kg body weight) containing 32 % α-TCT, 2 % β-TCT, 27 % γ-TCT, 14 % δ-TCT and 25 % α-tocopherol (α-TCP)." | ( Increased antioxidant capacity in the plasma of dogs after a single oral dosage of tocotrienols. Abraham, G; Raila, J; Rohn, S; Schweigert, FJ, 2011) | 0.59 |
| " Feed nutrients resulted in a dose-response relationship of these compounds in the egg yolk." | ( Supplementation of laying-hen feed with palm tocos and algae astaxanthin for egg yolk nutrient enrichment. Dolde, D; Walker, LA; Wang, T; Xin, H, 2012) | 0.38 |
| " When evaluating the efficacy of vitamin E prophylactic or therapeutic use in previous and future studies, it is critical to consider dosage to be administered, form of vitamin E and source (such as whether from synthetic or purified from natural sources)." | ( Vitamin E: a dark horse at the crossroad of cancer management. Cardenas, E; Ghosh, R, 2013) | 0.39 |
| " Unfortunately, despite their very significant radioprotectant activity, tocotrienols have very short plasma half-lives and require dosing at very high levels to achieve necessary therapeutic benefits." | ( Molecular dynamics guided design of tocoflexol: a new radioprotectant tocotrienol with enhanced bioavailability. Boerma, M; Breen, PJ; Compadre, CM; Ghosh, S; Hauer-Jensen, M; Kiaei, M; Singh, A; Thakkar, S; Varughese, KI; Zheng, G, 2014) | 0.63 |
| " Its potential should be evaluated further by varying the dosage and treatment duration." | ( Effects of annatto-derived tocotrienol supplementation on osteoporosis induced by testosterone deficiency in rats. Chin, KY; Ima-Nirwana, S, 2014) | 0.4 |
| " Recent expansive development of diverse nanoemulsion (NE) vehicles emphasized their vast potential to improve the effective dosing of different clinical and experimental drugs of lipophilic nature, such as T3." | ( Enhanced effectiveness of tocotrienol-based nano-emulsified system for topical delivery against skin carcinomas. Elbayoumi, T; Hoang, C; Nayel, A; Pham, J, 2016) | 0.43 |
| " In conclusion, the concentrations of vitamin E congeners and the expression of genes related to vitamin E status follow characteristic time-related changes during the transition from late gestation to early lactation but are unaffected by CLA supplementation at the dosage used." | ( Tocopherols and tocotrienols in serum and liver of dairy cows receiving conjugated linoleic acids or a control fat supplement during early lactation. Dänicke, S; Frank, J; Meyer, U; Rehage, J; Sadri, H; Sauerwein, H, 2015) | 0.76 |
| " Tocotrienols were measured in heart, liver and adipose tissue showing that chronic oral dosage delivered tocotrienols to these organs despite low or no detection of tocotrienols in plasma." | ( Anti-inflammatory γ- and δ-tocotrienols improve cardiovascular, liver and metabolic function in diet-induced obese rats. Brown, L; Fong, CW; Ward, LC; Wong, WY; Yap, WN, 2017) | 1.66 |
| " The present trial compares the antioxidant effectiveness following postprandial challenge of two different doses of α-T or palm T3-rich fraction (TRF) treatments and evaluates their dose-response effects on antioxidant status." | ( Antioxidant status following postprandial challenge of two different doses of tocopherols and tocotrienols. Cheng, HM; Fairus, S; Sundram, K, 2020) | 0.78 |
| " However, a significant dose-response effect was observed for plasma MDA throughout the 8-hour postprandial period." | ( Antioxidant status following postprandial challenge of two different doses of tocopherols and tocotrienols. Cheng, HM; Fairus, S; Sundram, K, 2020) | 0.78 |
| " The meta-analysis revealed that TRF supplementation at a dosage of 250-400 mg significantly decreased HbA1c (-0." | ( Effects of Tocotrienol-Rich Fraction Supplementation in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Abdul Kadir, K; Ahmad, B; M Palanisamy, UD; Phang, SCW, 2023) | 0.91 |
| Item | Process | Frequency |
|---|---|---|
| Snacks | core-ingredient | 2 |
| Chocolate candies | core-ingredient | 1 |
| Confectioneries | core-ingredient | 1 |
| Cocoa and its products | core-ingredient | 1 |
| Sweet snacks | core-ingredient | 1 |
| Class | Description |
|---|---|
| diterpenoid | Any terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 17.9008 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID51435 | Hypocholesterolemic activity in 6-week old male mormocholesterolemic chickens using experiment 2 | 1994 | Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4 | Inhibitors of cholesterol biosynthesis. 2. Hypocholesterolemic and antioxidant activities of benzopyran and tetrahydronaphthalene analogues of the tocotrienols. |
| AID86700 | Compound evaluated for percent inhibition of cholesterol synthesis from HMG-CoA Reductase in HepG2 cell | 1992 | Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20 | Hypocholesterolemic activity of synthetic and natural tocotrienols. |
| AID102346 | LDL oxidation assay as spectrophotometric determination of TBARS | 1994 | Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4 | Inhibitors of cholesterol biosynthesis. 2. Hypocholesterolemic and antioxidant activities of benzopyran and tetrahydronaphthalene analogues of the tocotrienols. |
| AID51439 | Hypocholesterolemic activity in 6-week old male mormocholesterolemic chickens using experiment 2 | 1994 | Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4 | Inhibitors of cholesterol biosynthesis. 2. Hypocholesterolemic and antioxidant activities of benzopyran and tetrahydronaphthalene analogues of the tocotrienols. |
| AID226925 | Compound oxidation potential using cyclic voltametry | 1994 | Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4 | Inhibitors of cholesterol biosynthesis. 2. Hypocholesterolemic and antioxidant activities of benzopyran and tetrahydronaphthalene analogues of the tocotrienols. |
| AID232598 | Ratio of HDL/total cholesterol value | 1994 | Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4 | Inhibitors of cholesterol biosynthesis. 2. Hypocholesterolemic and antioxidant activities of benzopyran and tetrahydronaphthalene analogues of the tocotrienols. |
| AID86701 | Compound evaluated for percent inhibition of cholesterol synthesis from [14C]acetate in HepG2 cell | 1992 | Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20 | Hypocholesterolemic activity of synthetic and natural tocotrienols. |
| AID83297 | In vitro suppression of HMG-CoA reductase (HMGR) in Hep G2 cells | 1994 | Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4 | Inhibitors of cholesterol biosynthesis. 2. Hypocholesterolemic and antioxidant activities of benzopyran and tetrahydronaphthalene analogues of the tocotrienols. |
| AID86398 | In vitro inhibition of cholesterol biosynthesis in Hep G2 cells | 1994 | Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4 | Inhibitors of cholesterol biosynthesis. 2. Hypocholesterolemic and antioxidant activities of benzopyran and tetrahydronaphthalene analogues of the tocotrienols. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (0.25) | 18.7374 |
| 1990's | 22 (2.70) | 18.2507 |
| 2000's | 227 (27.85) | 29.6817 |
| 2010's | 426 (52.27) | 24.3611 |
| 2020's | 138 (16.93) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (46.24) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 51 (6.10%) | 5.53% |
| Reviews | 133 (15.91%) | 6.00% |
| Case Studies | 1 (0.12%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 651 (77.87%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Randomized, Double Blinded, Placebo-controlled Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults [NCT03444298] | Phase 2 | 23 participants (Actual) | Interventional | 2018-06-08 | Completed | ||
| Efficacy of Vitamin C, Vitamin E and Their Combination for Treatment of Restless Legs Syndrome in Hemodialysis Patients: a Randomized Double-blind, Placebo-controlled Trial [NCT01125033] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Malaysian Tocotrienol Rich Fraction: Immunomodulatory Effect in Women With Breast Cancer [NCT03855423] | 12 participants (Anticipated) | Interventional | 2019-02-18 | Recruiting | |||
| Effects of Supplementation With Tocotrienol on Inflammation, Oxidative Stress and Microbiota of Chronic Kidney Disease Patients [NCT04900532] | 61 participants (Actual) | Interventional | 2019-05-01 | Active, not recruiting | |||
| Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure [NCT02911688] | Phase 2 | 18 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| A 4-month, Randomized, Placebo-controlled, Double-blind Intervention of Antioxidant Supplementation in Overweight Children Enrolled in an Outpatient Weight-loss Program: Effects on Oxidative and Inflammatory Markers, Hepcidin, Iron Status, and Components [NCT01316081] | 45 participants (Actual) | Interventional | 2011-03-31 | Completed | |||
| Effectiveness of Tocotrienol-rich Fraction Combined With Tamoxifen in the Management of Women With Early Breast Cancer: A Pilot Clinical Trial [NCT01157026] | 240 participants (Actual) | Interventional | 2001-11-30 | Completed | |||
| A Randomized Double-Blind Placebo-Controlled Study Of Oral Coenzyme Q10 To Relieve Self-Reported Cancer Treatment Related Fatigue In Breast Cancer Patients [NCT00096356] | Phase 1 | 236 participants (Actual) | Interventional | 2004-08-27 | Completed | ||
| Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer: A Marker Based Phase II Trial [NCT04175470] | Phase 2 | 60 participants (Anticipated) | Interventional | 2019-10-29 | Recruiting | ||
| Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer [NCT00006392] | Phase 3 | 35,533 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| Preoperative Use of Tocotrienol Associated With Personalized Nutritional and Psychoeducational Support in Women With Primary Breast Cancer. [NCT04496492] | Phase 2 | 50 participants (Actual) | Interventional | 2016-02-09 | Completed | ||
| Cardioprotective Synergy of Smoking Cessation and γ-Tocopherol in Restoring Vascular Endothelial Function [NCT01314443] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Phase III, Single Centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of Oral Vitamin E (Mixed Tocotrienol) for 6 Months in Patients With Moderate Acute Ischemic Stroke [NCT02263924] | Phase 3 | 150 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Antioxidant Micronutrients in Malaria:a Randomised Clinical Trial [NCT01152931] | Phase 3 | 10 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| The Effect of Alpha-tocopherol in Hemolysis and Oxidative Stress Marker on the Red Cell [NCT03948737] | 40 participants (Actual) | Interventional | 2016-12-30 | Completed | |||
| Mechanism of Absorption and Distribution of Tocotrienols Under Different Food Status [NCT01185769] | 10 participants (Actual) | Interventional | 2009-09-30 | Completed | |||
| A Double Blind Placebo Controlled Study On The Neuroprotective And Anti-Atherogenic Effects Of Palm TocotrienolRich Fraction(Palm Vitamin E) [NCT00753532] | Phase 2 | 241 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Randomized Clinical Trial Evaluating Combined Pentoxifylline-tocopherol-clodronate vs Placebo in Radiation-induced Brachial Plexopathy: the PENTOCLO Trial [NCT01291433] | Phase 3 | 59 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Effect of the Application of Vitamin E Ointment, Over Staple Lines and Anastomosis in Roux-en-Y Gastric Bypass, on Postoperative Pain [NCT03765827] | Phase 3 | 140 participants (Actual) | Interventional | 2018-12-05 | Completed | ||
| NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment [NCT01002547] | Phase 4 | 105 participants (Actual) | Interventional | 2010-06-24 | Completed | ||
| Effect of Subcutaneous Sterile Vitamin E Ointment on Incisional Surgical-site Infection Following Elective Laparoscopic Colorectal Cancer Surgery [NCT02820948] | Phase 3 | 108 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Effects of a Tocotrienol-Enriched Fraction of Palm Oil and Chinese Red Yeast Rice on Serum Lipids in Hypercholesterolemic Subjects [NCT02142569] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2013-10-30 | Withdrawn(stopped due to We were unable to procure the supplement for this study.) | ||
| Phase 1b to Assess Safety, Tolerability, Pharmacokinetic Profile, and Antimalarial Activity of Single Doses of Co-administered OZ439and PQP Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Adult Volunteers [NCT03542149] | Phase 1 | 24 participants (Actual) | Interventional | 2018-04-23 | Completed | ||
| A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E [NCT05939726] | 90 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | |||
| Anti-Inflammatory Effect of Tocotrienol Supplementation in Subjects With Moderately Elevated Inflammation [NCT03532763] | 180 participants (Anticipated) | Interventional | 2018-04-19 | Recruiting | |||
| Effect of Gamma Tocopherol Supplementation on Neutrophil Response to 20,000 EU of Clinical Center Reference Endotoxin in Normal Adults [NCT00631085] | Phase 1 | 18 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Interventional Strategy in Tackling Emerging Non-alcoholic Fatty Liver Disease in Childhood Obesity [NCT05905185] | Phase 4 | 29 participants (Actual) | Interventional | 2020-01-01 | Completed | ||
| A Randomized Investigation of Side Effects to FOLFOXIRI in Combination With Tocotrienol or Placebo as First Line Treatment of Metastatic Colorectal Cancer [NCT02705300] | Phase 2 | 70 participants (Actual) | Interventional | 2016-05-06 | Active, not recruiting | ||
| "The Effect of KB-120 Small Molecular Nutrient in Women With Decreased Ovarian Reserve" [NCT06081257] | 80 participants (Anticipated) | Interventional | 2023-10-15 | Not yet recruiting | |||
| A Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia [NCT00985777] | Phase 1 | 26 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Efficacy of Alpha Tocopherol and New Biomarker (Urine NGAL) for Prevention and Early Diagnosis of Contrast-induced Nephropathy in CKD Patients Undergoing Elective Coronary Procedures [NCT01061320] | Phase 3 | 200 participants (Anticipated) | Interventional | 2010-01-31 | Enrolling by invitation | ||
| PentoxIfylline and Tocopherol for the Treatment of Post-radiotherapy Fibrosis in Head and Neck Cancer Patients: a Feasibility Study [NCT03723291] | Phase 1 | 50 participants (Anticipated) | Interventional | 2019-09-01 | Recruiting | ||
| Osteoradionecrosis and PENTOCLO Protocol: Retrospective Study. [NCT04097847] | 96 participants (Actual) | Observational | 2017-06-02 | Completed | |||
| Effects of Coenzyme Q10 in Parkinson Disease - Phase III [NCT00740714] | Phase 3 | 600 participants (Actual) | Interventional | 2008-12-31 | Terminated(stopped due to The investigational drug is unlikely to demonstrate efficacy over placebo for this indication. However, no safety issues were discovered.) | ||
| In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics [NCT00836368] | Phase 1 | 25 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Evaluation of a Short Course of Gamma Tocopherol Supplementation in Adult Subjects [NCT02610829] | 10 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| A Randomized Controlled Project to Study the Efficacy of Combined Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis [NCT01384578] | Phase 3 | 0 participants (Actual) | Interventional | 2011-07-31 | Withdrawn(stopped due to Lack of funds) | ||
| The PENTO Protocol in Medication-related Osteonecrosis of the Jaw [NCT05795647] | Phase 2 | 17 participants (Anticipated) | Interventional | 2023-11-20 | Not yet recruiting | ||
| Tocotrienol Against the Progression of End Stage Liver Disease [NCT02581085] | Phase 2 | 70 participants (Anticipated) | Interventional | 2019-11-01 | Recruiting | ||
| Single-site, Open-label, Dose-ranging, Efficacy, and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated CF [NCT00889434] | 7 participants (Actual) | Interventional | 2011-11-01 | Completed | |||
| The Effect of Supplemental Adjuvants for Intracellular Nutrition and Treatment on Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration [NCT00893724] | 60 participants (Anticipated) | Interventional | 2009-06-30 | Active, not recruiting | |||
| CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD) [NCT00235716] | Phase 3 | 613 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| The Effect of Vitamin E and Docosahexaenoic Acid Ethyl Ester on Non-Alcoholic Fatty Liver Disease (NAFLD) - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD) [NCT04198805] | Phase 2 | 205 participants (Actual) | Interventional | 2020-01-03 | Completed | ||
| Exploratory, Double-blind, Randomized, Placebo Controlled Study of AMP-886 in the Elderly [NCT01953172] | 12 participants (Actual) | Interventional | 2013-10-31 | Terminated(stopped due to Recruitment problems) | |||
| A Phase 2A Clinical Trial of EPI-743 (Vincerinone™) on Visual Function in Friedreich's Ataxia Patients With Point Mutations [NCT01962363] | Phase 2 | 4 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| A Clinical Study on the Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus [NCT01973400] | Phase 3 | 300 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| [NCT02011906] | Phase 4 | 20 participants (Anticipated) | Interventional | 2013-10-31 | Enrolling by invitation | ||
| Actions of Dietary Tocotrienols on Obesity [NCT03705845] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2019-03-15 | Recruiting | ||
| Tocotrienol as a Nutritional Supplement in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) [NCT02644252] | Phase 3 | 79 participants (Actual) | Interventional | 2016-01-31 | Terminated(stopped due to The trial was ended prematurely because of a poor accrual rate) | ||
| Vitamin E Supplementation in Burn Patients [NCT01413620] | Phase 1 | 0 participants (Actual) | Interventional | 2011-08-31 | Withdrawn | ||
| Effects of a High-dose Concentrate of n-3 Fatty Acids or Corn Oil Introduced Early After an Acute Myocardial Infarction on Serum Triacylglycerol and High-density Lipoprotein (HDL)- Cholesterol [NCT01422317] | Phase 3 | 300 participants (Actual) | Interventional | 1995-09-30 | Completed | ||
| Evaluation of the Clinical Benefit of a Spa Care on the Evolution of Late Fibrosis After Postoperative Radiotherapy for Breast Cancer in Remission [NCT02898376] | Phase 3 | 142 participants (Anticipated) | Interventional | 2018-12-31 | Not yet recruiting | ||
| Phase III Study Analyzing the Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss [NCT00400387] | Phase 3 | 449 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Phase II Study of the Use of Pentoxifylline and a-Tocopherol in the Treatment of Chronic Breast Pain Associated With Breast Radiotherapy [NCT00188669] | Phase 2 | 48 participants (Anticipated) | Interventional | 2002-07-31 | Terminated(stopped due to date: August 2006. No annual renewal) | ||
| Tocotrienols Supplementation in School Going Children With Attention Deficit/Hyperactivity Disorder(ADHD) - A Randomized Controlled Trial [NCT01855984] | Phase 2/Phase 3 | 160 participants (Anticipated) | Interventional | 2012-02-29 | Completed | ||
| Human Blood Outcomes Following Tocotrienol Supplementation - Nutrition Phase IIB NUTRITION PHASE IIB [NCT01858311] | 300 participants (Actual) | Observational | 2013-03-31 | Completed | |||
| Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer [NCT02909751] | Phase 2 | 80 participants (Actual) | Interventional | 2016-09-14 | Completed | ||
| To Investigate the Effectiveness of Adjuvant Supplements Prior to in Vitro Fertilization Cycles [NCT05471453] | 90 participants (Anticipated) | Interventional | 2022-03-02 | Recruiting | |||
| Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF [NCT02690064] | 13 participants (Actual) | Interventional | 2015-04-30 | Active, not recruiting | |||
| Pentoxifylline, Atorvastatin, and Vitamin E (PAVE) as Treatment for Radiation-Induced Erectile Dysfunction [NCT03830164] | Phase 2 | 14 participants (Actual) | Interventional | 2019-11-20 | Completed | ||
| Effects of a Tocotrienol-Enriched Fraction of Palm Oil on Serum Lipids in Hypercholesterolemic Subjects [NCT02634606] | Phase 3 | 13 participants (Actual) | Interventional | 2011-03-22 | Terminated(stopped due to Unable to obtain supplement for this study. Unable to recruit.) | ||
| ASSESSMENT OF INTERMEDIATE ENDPOINT BIOMARKERS TO 13-CIS RETINOIC ACID WITH OR WITHOUT ALPHA TOCOPHEROL OR OBSERVATION [NCT00002586] | Phase 2 | 96 participants (Actual) | Interventional | 1993-01-31 | Completed | ||
| Comparison of Gamma-tocopherol Supplementation in Allergic Asthmatics and Normal Volunteers [NCT00386178] | Phase 1 | 16 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Vitamin E Versus Vitamin E Plus Pentoxiphyllin in Patients With Nonalcoholic Steatohepatitis: A Prospective Randomized Clinical Trial [NCT01279434] | 0 participants (Actual) | Interventional | 2012-01-31 | Withdrawn | |||
| Trace Element Replenishment Study in Hemodialysis Patients [NCT01473914] | Phase 3 | 150 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| Advances in the Management of Mandibular Osteoradionecrosis: Pentoxifylline and Tocopherol as Medical Treatment [NCT02368457] | Phase 4 | 24 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Tocopherols and Alpha Lipoic Acid Treatment Chronic Kidney Disease (TALAT) [NCT00308971] | Phase 2 | 62 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Multicentre, Placebo-controlled Trial of Eicosapentaenoic Acid (EPA) and Antioxidant Supplementation in the Treatment of Schizophrenia and Related Disorders [NCT00419146] | Phase 2/Phase 3 | 99 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| VEAPS: Vitamin E Atherosclerosis Prevention Study [NCT00114387] | Phase 2/Phase 3 | 353 participants | Interventional | 1996-07-31 | Completed | ||
| Tocotrienols Supplementation for Postmenopausal Women With Low Muscle Strength [NCT03708354] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2019-04-15 | Withdrawn(stopped due to Difficulties in Recruiting) | ||
| Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol [NCT00678834] | Early Phase 1 | 80 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Phase II Study of the Use of Pentoxifylline and Vitamin E in the Treatment of Late Radiation Related Injuries [NCT00188552] | Phase 2 | 50 participants (Anticipated) | Interventional | 2002-07-31 | Terminated(stopped due to May 2007: No annual renewal) | ||
| Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol Supplements [NCT00466596] | Phase 1 | 8 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Impact of Oral Versatile Antioxidants on Glaucoma Progression:Comparative Early Results [NCT01544192] | Phase 3 | 60 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Efficacy and Safety of the Association With Pentoxyphilline and Tocopherol on the Fibrosis in Patients With Chronic Hepatitis C [NCT00119119] | Phase 3 | 100 participants | Interventional | 2002-02-28 | Terminated | ||
| Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE) [NCT00040378] | 4,246 participants (Actual) | Observational | 2002-05-31 | Completed | |||
| The Respiratory Ancillary Study (RAS) to SELECT [NCT00063453] | Phase 3 | 2,920 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| A Parallel, Evaluator-Blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Two Marketed Topical Skin Protectants Containing Zinc Oxide in Children With Diaper Rash [NCT00219466] | Phase 4 | 112 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| A Randomized Double Blind Placebo Controlled Clinical Trial Aim to Assess the Efficacy of Vitamin E Formulation (Tocopherol) in the Treatment of Chemotherapy Induced Stomatitis in Patients Undergoing Stem Cell Transplantation [NCT00162526] | Phase 2 | 30 participants (Anticipated) | Interventional | 2005-12-31 | Withdrawn(stopped due to the PI is no longer work at Hadassah) | ||
| Study of the Effect of Oral Supplementation With Vitamin E on Circulating Oxidative Markers, Hemodialysis Vascular Access Occlusion, and Clinical Events in Patients With End Stage Renal Failure Treated by Hemodialysis [NCT00410449] | 35 participants | Observational | 2001-05-31 | Completed | |||
| S0000D: A Study of the Effect of Vitamin E and/or Selenium on Adenomatous Colorectal Polyps (ACP) in Participants Enrolled in SELECT [NCT00706121] | Phase 3 | 8,094 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| S0000B: Prevention of Cataract and Age-Related Macular Degeneration With Vitamin E and Selenium - SELECT Eye Endpoints (SEE) [NCT00784225] | Phase 3 | 13,475 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Effect of Tocotrienols on Bone Health: A Pilot Study [NCT02058420] | Phase 1/Phase 2 | 78 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| DBPCR Clinical Trial for Treatment of Rhinitis With Intranasal Vitamin E [NCT00281307] | 10 participants (Actual) | Interventional | 2005-12-07 | Terminated(stopped due to Due to a substantial response to placebo an interim analysis indicated the need for a larger than expected study population to achieve the level of significance) | |||
| Effects of Tocotrienols Supplementation on Platelet Aggregation in Subjects With Metabolic Syndrome [NCT01631838] | 32 participants (Actual) | Interventional | 2012-05-31 | Completed | |||
| A Randomized Placebo-controlled Double-blind Pilot / Phase II Study to Assess the Efficacy and Safety of HOV-12020 in Patients With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) [NCT04658823] | Phase 2 | 50 participants (Anticipated) | Interventional | 2020-12-21 | Active, not recruiting | ||
| Enhancing Treatment of Iron Deficiency and Iron Deficiency Anemia With an Antioxidant, Vitamin E [NCT01700426] | Phase 1 | 44 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Vitamin E Supplementation in Burned Patients [NCT01749371] | Phase 2/Phase 3 | 31 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Treatment of Radiation-induced Fibrosis in the Upper Aerodigestive Tract Cancer by a Combination of Pentoxifylline-tocopherol and Hyperbaric Oxygen [NCT01822405] | Phase 2 | 42 participants (Anticipated) | Interventional | 2010-07-31 | Recruiting | ||
| Effects of Inclusion of Sunflower Oil, Vitamin E and Selenium in the Diet of Dairy Cows on Milk Composition and Its Influence on Nutrition and Health of Elderly [NCT02980094] | 132 participants (Actual) | Interventional | 2011-08-31 | Completed | |||
| A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Vitamin E δ-Tocotrienol Following Single Dose Administration in Healthy Subjects [NCT01446952] | Phase 1 | 18 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Vitamin E δ-Tocotrienol Following Multiple Dose Administration in Healthy Subjects [NCT01450046] | Phase 1 | 18 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Study of the Absorption of Vitamin E Water-soluble Form (Pegylated) in the Familial Hypocholesterolemia With Chylomicron Retention [NCT01457690] | Phase 3 | 14 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Phase III Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer Prior to Prostatectomy or Brachytherapy [NCT00809458] | Phase 3 | 15 participants (Actual) | Interventional | 2008-09-30 | Terminated(stopped due to Low rate of accrual.) | ||
| A Randomized, Double-Blind, Placebo-Controlled Study, to Assess the Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL) [NCT04704063] | Phase 2 | 170 participants (Anticipated) | Interventional | 2021-01-01 | Active, not recruiting | ||
| Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ): A Prospective, Randomized Controlled Trial to Evaluate a Novel Non-operative Treatment [NCT03040778] | Phase 3 | 100 participants (Anticipated) | Interventional | 2018-04-01 | Enrolling by invitation | ||
| Palm Tocotrienols in Chronic Hemodialysis (PATCH Study) [NCT02358967] | 280 participants (Actual) | Interventional | 2017-06-15 | Completed | |||
| Prospective, Randomized, Single-blind, Multinational, Long-term Study for the Evaluation of the Clinical Outcome, Oxidation Profile and Wear Analysis of Medium Cross-linked Polyethylene With and Without Vitamin E for Total Knee Arthroplasty [NCT04618016] | 560 participants (Anticipated) | Observational | 2021-03-08 | Recruiting | |||
| Phase 1a: A Randomized, 2-period Cross-over Study to Compare the Bioavailability of Gamma-Delta Tocotrienol (GDT) With That of Tocotrienol Rich Fraction (TRF) in Twelve Healthy Subjects [NCT01571921] | Phase 1 | 12 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Effect of Stellate Ganglion Block on Meniere's Disease [NCT01574313] | Phase 4 | 20 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Human Blood Outcomes Following Tocotrienol Supplementation - NUTRITION Phase I and Phase IIA [NCT01578629] | Phase 1/Phase 2 | 210 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Efficacy Of Tocotrienol a Natural Vitamin E In Biopsy Wound. [NCT01579227] | 101 participants (Anticipated) | Observational | 2012-01-31 | Active, not recruiting | |||
| [NCT01594346] | Phase 3 | 349 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
| Effect of Antioxidant Cocktail in Beta-thalassemia/Hb E Patients [NCT01597765] | 60 participants (Actual) | Interventional | 2009-06-30 | Completed | |||
| A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating The Safety And Efficacy Of An Oral Supplement Containing Astaxanthin (2 mg) + Lycopene (1.8 mg) + D-Alpha-Tocopherol (10 IU) For The Treatment Of Skin Aging [NCT03460860] | 100 participants (Actual) | Interventional | 2018-03-05 | Completed | |||
| A Randomised Double-blinded Placebo Controlled Study on the Effect of Topical Palm Tocotrienol on Skin Biophysical Properties [NCT05787743] | 41 participants (Actual) | Interventional | 2023-07-17 | Terminated(stopped due to Sponsor withdrawal) | |||
| Therapeutic Effect of Semaglutide on Nonalcoholic Fatty Liver Disease in Obesity and/or Type 2 Diabetes Mellitus [NCT05813249] | Phase 4 | 180 participants (Anticipated) | Interventional | 2023-02-15 | Recruiting | ||
| The Efficacy and Safety of Vitamin E Mixed Tocotrienols In Patients With Amyotrophic Lateral Sclerosis (ALS) : A Pilot Exploratory Study [NCT04140136] | Phase 2 | 20 participants (Anticipated) | Interventional | 2019-06-17 | Recruiting | ||
| Provision of Antioxidant Therapy in Hemodialysis (PATH) Study [NCT00237718] | Phase 2 | 385 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Lipid Peroxidation and Options Antioxidant Therapy for Secondary Lymphedema of the Lower Extremities [NCT04360889] | Phase 4 | 120 participants (Actual) | Interventional | 2019-09-01 | Completed | ||
| Effects of Vitamin E (Alfa-Tocoferol) Supplementation on Isoprostane and Lipid Profile of Obese Adolescent in Jakarta, Indonesia [NCT03358524] | Phase 4 | 69 participants (Actual) | Interventional | 2017-09-28 | Completed | ||
| Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E [NCT01792115] | Phase 2 | 22 participants (Actual) | Interventional | 2013-05-01 | Completed | ||
| Preventive Strategies in Colorectal Carcinogenesis Production and Meat Processing [NCT02473302] | 24 participants (Actual) | Interventional | 2014-04-30 | Completed | |||
| Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma [NCT01897792] | Phase 2 | 11 participants (Actual) | Interventional | 2013-05-31 | Terminated(stopped due to Inability to recruit patients that meet inclusion criteria.) | ||
| Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women [NCT00862433] | Phase 1 | 50 participants (Actual) | Interventional | 2014-10-10 | Completed | ||
| An Examination Into the Effects of a Nutraceutical Supplement on Cognition, Stress, and Eye and Skin Health in Adults With Self-reported Cognitive Complaints: a Randomised, Double-blind, Placebo-controlled Trial [NCT05941949] | 110 participants (Anticipated) | Interventional | 2023-07-05 | Recruiting | |||
| Faecal Microbiome as Determinant of the Effect of Diet on Colorectal-cancer Risk: Comparison of Meat Based Versus Pesco-vegetarian Diets (MeaTIc) [NCT03416777] | 103 participants (Actual) | Interventional | 2019-06-01 | Completed | |||
| Efficacy of Natural Vitamin E Tocotrienol on the Treatment of Surgical Scars [NCT00700791] | Early Phase 1 | 168 participants (Anticipated) | Interventional | 2008-07-31 | Terminated(stopped due to The PI moved to another Institution) | ||
| Safety of Tocotrienols in Atrial Fibrillation After Coronary Artery Bypass Grafting Surgery: A Randomized Controlled Exploratory Trial [NCT03807037] | Phase 2/Phase 3 | 250 participants (Actual) | Interventional | 2018-12-17 | Completed | ||
| Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS [NCT02104505] | Phase 1/Phase 2 | 23 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
| Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer. A Randomized Phase II Marker Trial [NCT04245865] | Phase 2 | 74 participants (Anticipated) | Interventional | 2020-06-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||